Patients with DLBCL demonstrated good clinical responses and survival outcomes when treated with CHOP ± R, but patients with BL could not tolerate chemotherapy with CODOX-M/IVAC ± R due to more severe toxicity; and their clinical response and survival outcomes were poor due to poor performance status and lower CD4 counts. Here, CD4 is linked to diffuse large B-cell lymphoma.